The hypnotic agent is currently supported by a marketing network of 1,500 reps in the U.S., Searle said. The company also reported that Ambien has 54% of new prescriptions and 89% of sales in the hypnotic market. Figures reported by Searle's Ambien marketing partner Sanofi-Synthelabo in "The Pink Sheet" (Sept. 6, p. 14) were different from those of Searle's because of different market definitions
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth